![]() | |
Clinical data | |
---|---|
Trade names | Carbaglu, Ucedane |
Other names | (S)-2-ureidopentanedioic acid |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 30% |
Protein binding | Undetermined |
Metabolism | Partial |
Elimination half-life | 4.3 to 9.5 hours |
Excretion | Fecal (60%) and kidney (9%, unchanged) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.116.323 |
Chemical and physical data | |
Formula | C6H10N2O5 |
Molar mass | 190.155 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Carglumic acid, sold under the brand name Carbaglu among others, is used for the treatment of hyperammonaemia.[2][5][6]
Carglumic acid is a carbamoyl phosphate synthetase 1 (CPS 1) activator.[2]
The most common adverse effects include vomiting, abdominal pain, pyrexia (fever), and tonsillitis, anemia, diarrhea, ear infection, other infections, nasopharyngitis, decreased hemoglobin levels, and headache.[2]
It was approved for medical use in the United States in March 2010.[7] Carglumic acid is an orphan drug.[8][9] It is available as a generic medication.[10]
Carglumic acid is indicated for the treatment of acute hyperammonemia and chronic hyperammonemia.[2][3][4]